42006 Search Results


pta 7905  (ATCC)
91
ATCC pta 7905
Pta 7905, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pta 7905/product/ATCC
Average 91 stars, based on 1 article reviews
pta 7905 - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier
ne dlg  (Santa Cruz Biotechnology)
85
Santa Cruz Biotechnology ne dlg
Ne Dlg, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ne dlg/product/Santa Cruz Biotechnology
Average 85 stars, based on 1 article reviews
ne dlg - by Bioz Stars, 2026-02
85/100 stars
  Buy from Supplier
vantictumab ma5-42006  (Fisher Scientific)
90
Fisher Scientific vantictumab ma5-42006
Modulation of WNT signaling controls AF closure. (A-D) Wholemount Alizarin Red and Alcian Blue staining at E18.5 and P5 showing that Scx-Cre;Ctnnb1 GOF mice exhibit a wide-open AF that fails to close compared to littermate controls. n =3 littermate pairs per stage. (E-G) A WNT inhibitor cocktail composed of recombinant mouse WIF1 protein and <t>vantictumab</t> was administered at P3 through a single injection under the scalp in the area above the AF. (E) Wholemount Alizarin Red and Alcian Blue staining of a treated control collected at P7 showed that the treatment had no negative effects on calvarial bone formation and AF closure. (F) Wholemount skeletal stains of three treated Wnt1-Cre;Fgfr2 −/− littermates showed that AF closure is partially restored. (G) Quantification of the AF area at P7 in control and Wnt1-Cre;Fgfr2 −/− mice that were treated (Tx) with WIF1/vantictumab at P3 or untreated.
Vantictumab Ma5 42006, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vantictumab ma5-42006/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
vantictumab ma5-42006 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
programmable dc power supply 42006-100-25  (QuadTech Inc)
90
QuadTech Inc programmable dc power supply 42006-100-25
Modulation of WNT signaling controls AF closure. (A-D) Wholemount Alizarin Red and Alcian Blue staining at E18.5 and P5 showing that Scx-Cre;Ctnnb1 GOF mice exhibit a wide-open AF that fails to close compared to littermate controls. n =3 littermate pairs per stage. (E-G) A WNT inhibitor cocktail composed of recombinant mouse WIF1 protein and <t>vantictumab</t> was administered at P3 through a single injection under the scalp in the area above the AF. (E) Wholemount Alizarin Red and Alcian Blue staining of a treated control collected at P7 showed that the treatment had no negative effects on calvarial bone formation and AF closure. (F) Wholemount skeletal stains of three treated Wnt1-Cre;Fgfr2 −/− littermates showed that AF closure is partially restored. (G) Quantification of the AF area at P7 in control and Wnt1-Cre;Fgfr2 −/− mice that were treated (Tx) with WIF1/vantictumab at P3 or untreated.
Programmable Dc Power Supply 42006 100 25, supplied by QuadTech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/programmable dc power supply 42006-100-25/product/QuadTech Inc
Average 90 stars, based on 1 article reviews
programmable dc power supply 42006-100-25 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Modulation of WNT signaling controls AF closure. (A-D) Wholemount Alizarin Red and Alcian Blue staining at E18.5 and P5 showing that Scx-Cre;Ctnnb1 GOF mice exhibit a wide-open AF that fails to close compared to littermate controls. n =3 littermate pairs per stage. (E-G) A WNT inhibitor cocktail composed of recombinant mouse WIF1 protein and vantictumab was administered at P3 through a single injection under the scalp in the area above the AF. (E) Wholemount Alizarin Red and Alcian Blue staining of a treated control collected at P7 showed that the treatment had no negative effects on calvarial bone formation and AF closure. (F) Wholemount skeletal stains of three treated Wnt1-Cre;Fgfr2 −/− littermates showed that AF closure is partially restored. (G) Quantification of the AF area at P7 in control and Wnt1-Cre;Fgfr2 −/− mice that were treated (Tx) with WIF1/vantictumab at P3 or untreated.

Journal: Development (Cambridge, England)

Article Title: FGFR2 directs inhibition of WNT signaling to regulate anterior fontanelle closure during skull development

doi: 10.1242/dev.204264

Figure Lengend Snippet: Modulation of WNT signaling controls AF closure. (A-D) Wholemount Alizarin Red and Alcian Blue staining at E18.5 and P5 showing that Scx-Cre;Ctnnb1 GOF mice exhibit a wide-open AF that fails to close compared to littermate controls. n =3 littermate pairs per stage. (E-G) A WNT inhibitor cocktail composed of recombinant mouse WIF1 protein and vantictumab was administered at P3 through a single injection under the scalp in the area above the AF. (E) Wholemount Alizarin Red and Alcian Blue staining of a treated control collected at P7 showed that the treatment had no negative effects on calvarial bone formation and AF closure. (F) Wholemount skeletal stains of three treated Wnt1-Cre;Fgfr2 −/− littermates showed that AF closure is partially restored. (G) Quantification of the AF area at P7 in control and Wnt1-Cre;Fgfr2 −/− mice that were treated (Tx) with WIF1/vantictumab at P3 or untreated.

Article Snippet: Stock vantictumab (Fisher Scientific, MA5-42006) and recombinant WIF1 protein (R&D Systems, 135-WF-050) were diluted in sterile water to a final concentration of 1.1 mg/ml and 0.5 mg/ml, respectively.

Techniques: Staining, Recombinant, Injection, Control